...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.
【24h】

Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.

机译:主动和被动联合免疫可增强大鼠尼古丁免疫疗法的功效。

获取原文
获取原文并翻译 | 示例
           

摘要

Vaccination against nicotine reduces the behavioral effects of nicotine in rats, and it is under clinical evaluation as a treatment for tobacco addiction. Efficacy is limited by the need for high serum nicotine-specific antibody (NicAb) levels, and currently available nicotine vaccines do not uniformly generate the required NicAb levels. Passive immunization with a nicotine-specific monoclonal antibody (Nic311) has also shown efficacy in rats. The principal aim of this study was to determine whether the combined use of vaccination and passive immunization would produce greater effects than vaccination alone on nicotine pharmacokinetics and locomotor sensitization (LMS) to nicotine. Rats were treated with vaccination alone, Nic311 alone, both, or neither, and then they were administered 10 daily injections of 0.3 mg/kg nicotine s.c. Treatment with Nic311 or vaccination alone increased the binding of nicotine in serum, reduced the unbound serum nicotine concentration and nicotine distribution to brain, and attenuated the development of LMS. Combined use of vaccination and passive immunization produced higher total serum NicAb levels, greater changes in nicotine pharmacokinetics, and a greater attenuation of LMS than either treatment alone. The total serum NicAb concentration was significantly correlated with brain nicotine levels and locomotor activity. These data indicate that providing higher serum NicAb concentrations improves the efficacy of immunotherapy against nicotine and that supplementing vaccination with passive immunization is a potential strategy to accomplish this.
机译:针对尼古丁的疫苗接种会降低尼古丁在大鼠中的行为效果,目前正在临床评估中,作为烟瘾的治疗方法。功效受到对高血清尼古丁特异性抗体(NicAb)水平的需求的限制,并且当前可用的尼古丁疫苗不能统一产生所需的NicAb水平。尼古丁特异性单克隆抗体(Nic311)的被动免疫在大鼠中也显示出功效。这项研究的主要目的是确定联合使用疫苗接种和被动免疫是否比单独接种对尼古丁的药代动力学和运动致敏性(LMS)产生更大的影响。给大鼠单独接种疫苗,单独使用Nic311接种,或两者都不接种,然后每天注射10次,每次0.3 mg / kg尼古丁皮下注射。单独使用Nic311进行治疗或接种疫苗可增加血清中尼古丁的结合力,降低未结合的血清尼古丁浓度和尼古丁向大脑的分布,并减弱LMS的发展。与单独使用任何一种疗法相比,疫苗接种和被动免疫的结合使用可产生更高的总血清NicAb水平,尼古丁药代动力学变化更大,LMS衰减更大。血清总NicAb浓度与脑尼古丁水平和运动能力显着相关。这些数据表明,提供更高的血清NicAb浓度可提高针对尼古丁的免疫疗法的效力,并且以被动免疫补充疫苗接种是实现这一目标的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号